Stephen Johnson

Array ( [id] => 19641276 [patent_doc_number] => 20240415796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => EYEDROPS FOR AMELIORATING OR PREVENTING RETINAL CIRCULATION DISORDER AND RETINAL NEUROVASCULAR COUPLING DISORDER [patent_app_type] => utility [patent_app_number] => 18/253096 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17775056 [patent_doc_number] => 20220241405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => ALLERGEN DESENSITIZATION METHOD [patent_app_type] => utility [patent_app_number] => 17/523648 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17523648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18815945 [patent_doc_number] => 20230390284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => DEGRADANT COMPOUND IN A MEDICANT [patent_app_type] => utility [patent_app_number] => 18/250921 [patent_app_country] => US [patent_app_date] => 2021-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20721 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -131 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398013 [patent_doc_number] => 20220040103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/509774 [patent_app_country] => US [patent_app_date] => 2021-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17509774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519252 [patent_doc_number] => 20220105100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => SAFE BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT [patent_app_type] => utility [patent_app_number] => 17/494635 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519255 [patent_doc_number] => 20220105103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => SAFE USE OF BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT [patent_app_type] => utility [patent_app_number] => 17/494713 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19140374 [patent_doc_number] => 20240139153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression [patent_app_type] => utility [patent_app_number] => 18/044149 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626616 [patent_doc_number] => 20230285411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => DRUG FORMULATION CONTAINING SEPETAPROST [patent_app_type] => utility [patent_app_number] => 18/040894 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355290 [patent_doc_number] => 20220016086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/352698 [patent_app_country] => US [patent_app_date] => 2021-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18690865 [patent_doc_number] => 20230321024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => METHODS OF TREATING VISUAL DISORDERS USING DAILY LOW DOSING OF A RETINOID COMPOUND [patent_app_type] => utility [patent_app_number] => 17/998370 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17586467 [patent_doc_number] => 11324708 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-05-10 [patent_title] => Niclosamide formulations for treating disease [patent_app_type] => utility [patent_app_number] => 17/330067 [patent_app_country] => US [patent_app_date] => 2021-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 49615 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18352165 [patent_doc_number] => 20230140276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/800361 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17184015 [patent_doc_number] => 20210330900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE) [patent_app_type] => utility [patent_app_number] => 17/238045 [patent_app_country] => US [patent_app_date] => 2021-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17238045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441762 [patent_doc_number] => 20220062267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => METHODS OF ACUTE RESTORATION OF VASCULAR COMPLIANCE [patent_app_type] => utility [patent_app_number] => 17/215856 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17875 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17215856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946563 [patent_doc_number] => 20210205254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/205915 [patent_app_country] => US [patent_app_date] => 2021-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17205915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168648 [patent_doc_number] => 20210322318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE [patent_app_type] => utility [patent_app_number] => 17/192379 [patent_app_country] => US [patent_app_date] => 2021-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17192379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050607 [patent_doc_number] => 20210260041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => PHARMACEUTICAL COMPOSITIONS OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND THEIR USE FOR IMPROVING VISION [patent_app_type] => utility [patent_app_number] => 17/180532 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23646 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18268672 [patent_doc_number] => 20230089914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => COMPOSITIONS COMPRISING AXITINIB AND METHODS OF TREATING OCULAR DISORDERS [patent_app_type] => utility [patent_app_number] => 17/800874 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18250772 [patent_doc_number] => 20230077811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => ACTIVATION OF NEUROPEPTIDE RECEPTORS ON PLASMACYTOID DENDRITIC CELLS TO TREAT OR PREVENT OCULAR DISEASES ASSOCIATED WITH NEOVASCULARIZATION AND INFLAMMATION [patent_app_type] => utility [patent_app_number] => 17/798344 [patent_app_country] => US [patent_app_date] => 2021-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18270474 [patent_doc_number] => 20230091716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => Progesterone Combinations [patent_app_type] => utility [patent_app_number] => 17/904035 [patent_app_country] => US [patent_app_date] => 2021-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904035 [rel_patent_id] =>[rel_patent_doc_number] =>)